AU762039B2 - Gardos channel antagonists - Google Patents

Gardos channel antagonists Download PDF

Info

Publication number
AU762039B2
AU762039B2 AU28807/00A AU2880700A AU762039B2 AU 762039 B2 AU762039 B2 AU 762039B2 AU 28807/00 A AU28807/00 A AU 28807/00A AU 2880700 A AU2880700 A AU 2880700A AU 762039 B2 AU762039 B2 AU 762039B2
Authority
AU
Australia
Prior art keywords
substituent
compound
ring
acetamide
para
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU28807/00A
Other languages
English (en)
Other versions
AU2880700A (en
Inventor
Grant Andrew Mcnaughton-Smith
Gregory Cooksey Rigdon
Jonathan Walter Stocker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icagen Inc
Original Assignee
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen Inc filed Critical Icagen Inc
Publication of AU2880700A publication Critical patent/AU2880700A/en
Application granted granted Critical
Publication of AU762039B2 publication Critical patent/AU762039B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/11—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU28807/00A 1999-02-23 2000-02-10 Gardos channel antagonists Ceased AU762039B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13551199P 1999-02-23 1999-02-23
US60/135511 1999-02-23
US09/386,601 US6288122B1 (en) 1999-02-23 1999-08-31 Gardos channel antagonists
US09/386601 1999-08-31
PCT/US2000/003663 WO2000050026A1 (en) 1999-02-23 2000-02-10 Gardos channel antagonists

Publications (2)

Publication Number Publication Date
AU2880700A AU2880700A (en) 2000-09-14
AU762039B2 true AU762039B2 (en) 2003-06-19

Family

ID=26833406

Family Applications (1)

Application Number Title Priority Date Filing Date
AU28807/00A Ceased AU762039B2 (en) 1999-02-23 2000-02-10 Gardos channel antagonists

Country Status (16)

Country Link
US (1) US6288122B1 (enExample)
EP (1) EP1158971B1 (enExample)
JP (2) JP4038337B2 (enExample)
KR (1) KR100705726B1 (enExample)
CN (1) CN1193748C (enExample)
AP (1) AP1465A (enExample)
AT (1) ATE370728T1 (enExample)
AU (1) AU762039B2 (enExample)
BR (1) BR0008416A (enExample)
CA (1) CA2371857C (enExample)
DE (1) DE60036093T2 (enExample)
ES (1) ES2291191T3 (enExample)
HK (1) HK1045262B (enExample)
IL (2) IL145012A0 (enExample)
OA (1) OA11838A (enExample)
WO (1) WO2000050026A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004010A1 (en) * 2001-07-06 2003-01-16 Poseidon Pharmaceuticals A/S Carbonylamino derivatives useful for obtaining immune regulation
EP1465863B1 (en) 2002-01-04 2008-07-09 NeuroSearch A/S Potassium channel modulators
AU2003217810C9 (en) * 2002-02-28 2008-06-12 Icagen, Inc. Methods for treating diseases related to intraocular pressure
EP1644332A1 (en) * 2003-07-03 2006-04-12 Poseidon Pharmaceuticals A/S Diarylmethyl derivatives as potassium channel modulators
WO2005003143A1 (en) * 2003-07-03 2005-01-13 Poseidon Pharmaceuticals A/S Novel potassium channel modulators
WO2006084031A1 (en) * 2005-02-01 2006-08-10 Icagen, Inc. Imines as ion channel modulators
US20100056637A1 (en) * 2005-12-20 2010-03-04 Icagen, Inc. Treatment methods using triaryl methane compounds
CA2633805A1 (en) * 2005-12-20 2007-07-05 Icagen, Inc. Treatment methods using triaryl methane compounds
WO2009027292A1 (en) * 2007-08-24 2009-03-05 Neurosearch A/S Carbonylamino derivatives useful for the treatment of certain inflammatory disorders
US20090076157A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched senicapoc
KR101896430B1 (ko) * 2008-04-09 2018-09-10 세루스 코포레이션 적혈구 병원체 불활성화를 위한 개선된 퀀칭 방법
CN102272152B (zh) 2008-11-10 2014-05-28 贝林格尔.英格海姆国际有限公司 通过中电导钙激活钾通道调控细胞-细胞融合的组合物及方法
WO2016134353A1 (en) * 2015-02-20 2016-08-25 Children's Medical Center Corporation Methods for treating malaria using potassium channel inhibitors
EP3106155A1 (en) * 2015-06-15 2016-12-21 Universite d'Aix Marseille Treatment and diagnosis of hereditary xerocytosis
CN110177548A (zh) * 2016-10-25 2019-08-27 罗兰·斯塔尔 Senicapoc用于治疗神经性疼痛的用途
WO2018162426A1 (en) 2017-03-06 2018-09-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Treatment and diagnosis of hereditary xerocytosis
CN112020353A (zh) 2019-03-29 2020-12-01 深圳仁泰医药科技有限公司 2,2-双(4-氟苯基)-2-苯乙酰胺的晶型a及其制备方法和应用
US12186286B2 (en) * 2019-07-29 2025-01-07 Paracelsus Neuroscience Llc Use of senicapoc for treatment of stroke
CN115943138A (zh) * 2020-07-14 2023-04-07 阿迪玛生物有限责任公司 包含gardos通道拮抗剂的组合物及其用途
US20240024335A1 (en) * 2020-12-11 2024-01-25 Sanquin IP B.V. Treatment and prevention of anaemia of inflammation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034589A1 (en) * 1996-03-20 1997-09-25 President And Fellows Of Harvard College Triaryl methane compounds for sickle cell disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273992A (en) 1992-11-02 1993-12-28 Beth Israel Hospital Assoc. Inc. Method for reducing sickle erythrocyte dehydration and delaying the occurrence of erythrocyte sickling in-situ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034589A1 (en) * 1996-03-20 1997-09-25 President And Fellows Of Harvard College Triaryl methane compounds for sickle cell disease

Also Published As

Publication number Publication date
AU2880700A (en) 2000-09-14
HK1045262B (zh) 2005-07-29
AP1465A (en) 2005-09-22
JP4038337B2 (ja) 2008-01-23
CA2371857A1 (en) 2000-08-31
KR20020002393A (ko) 2002-01-09
JP2007262075A (ja) 2007-10-11
OA11838A (en) 2005-08-22
CA2371857C (en) 2008-07-29
IL145012A0 (en) 2002-06-30
KR100705726B1 (ko) 2007-04-11
ATE370728T1 (de) 2007-09-15
EP1158971A1 (en) 2001-12-05
WO2000050026A1 (en) 2000-08-31
CN1344158A (zh) 2002-04-10
BR0008416A (pt) 2002-01-29
AP2001002268A0 (en) 2001-09-30
DE60036093D1 (de) 2007-10-04
ES2291191T3 (es) 2008-03-01
DE60036093T2 (de) 2008-05-15
US6288122B1 (en) 2001-09-11
EP1158971B1 (en) 2007-08-22
HK1045262A1 (en) 2002-11-22
IL145012A (en) 2006-12-10
JP2002537331A (ja) 2002-11-05
CN1193748C (zh) 2005-03-23
EP1158971A4 (en) 2003-04-16

Similar Documents

Publication Publication Date Title
US6288122B1 (en) Gardos channel antagonists
US20100056637A1 (en) Treatment methods using triaryl methane compounds
JP2001521485A (ja) 鎌状赤血球症のためのトリアリールメタン化合物
US5783597A (en) 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
KR20110137321A (ko) 록소프로펜 유도체 및 그것을 함유하는 의약
US20090036538A1 (en) Treatment methods using triaryl methane compounds
US7005539B2 (en) Ferulic acid dimers and their pharmaceutically acceptable salts, their preparation and use thereof for treating dementia
ZA200106847B (en) Gardos channel antagonists.
US3890445A (en) Lactamimide derivatives useful as hypoglycemic agents
FI77840B (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara resorcinderivat.
US3193458A (en) Method of lowering blood cholesterol level
US20050014751A1 (en) Use of n-acyl homoserine lactones for the treatment of insulitis
US3457354A (en) Treatment of hypertension with 2-hydroxy (or amino) - 4,5 - dihydroxyphenethylamine derivatives
NZ206256A (en) 1-aroyl-4-oxo-2-pyrrolidinepropionic acid derivatives and pharmaceutical compositions
US12194029B1 (en) Ethyl-1-(substitutedbenzoyl)-5-methylpyrrolo[1,2-a]quinoline-3-carboxylates as anticancer agents
EP4549425A1 (en) Quinone-derived compounds and use thereof against leishmania spp
AU610558B2 (en) Saturated fatty acid amides as inhibitors of acyl-coa: cholesterol acyltransferase
RU2002738C1 (ru) Способ получени производных N-гидроксимочевин в виде R- или S-энантиомерных форм или их смеси, или их фармацевтически приемлемых солей с щелочным металлом
JPH0374673B2 (enExample)
JPS625417B2 (enExample)
CS250579B1 (en) Imidazole derivatives and method of their preparation
IT8222696A1 (it) Sali dell'ascido 5-(4clorobenzoil)-1,4 dimetil-2-pirrolacetico
JPS6045614B2 (ja) ジイン系ポリプレニルアルコ−ルおよびそれを含有する血圧降下剤
JPH0376302B2 (enExample)
HK1194302A1 (zh) 紫檀茋在制造用於治疗、缓解或预防焦虑的药物组合物中的应用

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)